Skip to content
Head to head

Vir Biotechnology vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: VIR · VRTX

Updated 2 minutes ago

1-year performance, rebased to 100

VIR +52.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
VIRVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price8.39515.02
Change today-5.41%-1.08%
1-year return+50.9%+22.0%
Market cap$1.56B$130.58B
52-week range5.45 – 14.38412.27 – 568.67
Valuation
P/E (TTM)-7.1133.14
P/E percentile, own 5-yr range11th99th
P/B1.746.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.1615.32
Net profit (TTM)$-588.62M$3.88B
Revenue (TTM)$302.45M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-207.7%+11.8%
Gross margin100.0%85.5%
Operating margin-69.9%33.1%
Net margin-61.1%30.7%
Free cash flow (TTM)$-141.82M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership87.0%96.8%
Insider activity (12mo)20 buy / 27 sell28 buy / 22 sell
Short interest (% of float)10.0%1.9%
Analyst consensus100% buy (8)95% buy / 5% hold (21)
Analyst price target$22 (+167%)$624 (+21%)
StockVane view
StockVane Quant RatingD (89)C (68)
Company
Employees3676,400
Founded20161989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.